CME (CME) Q3 2025 Earnings Call Transcript

CME Group reported Q3 revenue of $1.5 billion, down 3% year over year, but delivered record market data revenue of $203 million, adjusted EPS of $2.68, and an adjusted operating margin of 68.4%. Average daily volume reached 25.3 million contracts and crypto volume jumped more than 225% year over year, while management lowered 2025 adjusted operating expense guidance to $1.625 billion ex-license fees and kept capital returns robust with $455 million in quarterly dividends. The call also highlighted FanDuel and Google partnerships, 24/7 crypto trading plans, and the pending redeployment of about $1.5 billion from the OSTTRA sale.

Analysis

CME is turning into a higher-quality compounder, not because the quarter was flashy on the top line, but because the mix is shifting toward more durable, less cyclical monetization. The underappreciated lever is market data plus distribution: recurring data growth, index license longevity, and the ability to push new products through a large retail/channel network should widen the revenue base while preserving exceptional margins. That combination makes earnings less dependent on short-term volatility spikes, which is exactly what investors pay up for in exchange operators.

The biggest second-order effect is that CME is effectively using innovation to deepen liquidity while lowering customer acquisition friction for partners. 24/7 crypto, event contracts, FX Spot+, and BrokerTec Chicago all reinforce the same strategic moat: once CME becomes the default venue where cash, futures, and retail access intersect, competitors face a tougher economics hurdle to dislodge order flow. The FanDuel angle matters less as a standalone revenue event and more as a distribution catalyst that can normalize retail engagement without forcing CME to buy growth at a rich multiple.

The market is likely underestimating how much optionality sits in capital deployment after the asset sale. With a fortress balance sheet and a payout-heavy capital return profile, any incremental buyback authorization or special return can materially accelerate per-share growth even if core volume normalizes. The main risk is regulatory: sports-linked contracts and 24/7 market structure could invite delays or adverse guidance, and the stock could de-rate if investors conclude the growth narrative depends on unproven categories rather than core derivatives.

Near term, this is a quality-vs-growth debate: if volatility stays subdued, the base business still composes through fees, data, and mix. Longer term, the upside comes from CME becoming the plumbing layer for new retail and around-the-clock trading behaviors. The consensus may still be too focused on quarter-over-quarter transaction revenue and not enough on the fact that CME is converting its franchise into a multi-channel toll road with expanding adjacency monetization.

Key Decisions for Investors

• Long CME on a 3-6 month horizon; use pullbacks toward the 50-day moving average as entry. Risk/reward skews positive because recurring data revenue and capital returns can cushion softer transaction volumes.
• Buy CME Jan-2027 calls or call spreads to express optionality on 24/7 crypto and FanDuel distribution. Best asymmetry if regulatory clarity arrives before the market fully prices the retail expansion.
• Pair trade: long CME / short a lower-quality exchange or broker name with less recurring revenue mix. The spread should work if investors rotate toward durable fee and data compounding rather than cyclical trading beta.
• If the board announces a meaningful buyback or special dividend post-asset-sale review, add to CME immediately; that would be a direct per-share catalyst with limited fundamental risk.
• Avoid chasing headline upside in sports/event-contract enthusiasm until regulatory posture is clearer; if the stock gaps higher on that narrative, consider trimming and reallocating into core CME exposure on any retracement.